NGFN-PLUS
High-performance proteome analysis for biomarker discovery and elucidation of pathomechanisms
| Coordinator: | Prof. Dr. Katrin Marcus | |
| Institution: | Abt. Funktionelle Proteomik, Ruhr-Universität Bochum | |
| Homepage: | funktionelle-proteomik.de |
The concurrent capture of thousands of protein species makes proteomics to a highly powerful and innovative approach in the exploration of complex illnesses, like the Morbus Parkinson (MP). Our group has applied latest methods of proteomics to the analysis of different model systems of the MP as well as human samples. This allowed us a direct insight into the regulation of illness-related proteins. The genomic / transcriptomic attempts of the NGFN consortium were complemented and links were enabled between genomic and proteomic findings.
In total more than 400 differential proteins were identified in various MP-related projects. Hereto, model systems were used to examine mutational influences or to simulate the early phase of neurodegeneration. Besides various cell culture models also mouse models were investigated in which e.g. the influence of Parkinson's disease-related gene mutations were examined encoding for the protein alpha-synuclein (A30P and A53T) or the serine protease Omi/HtrA2 (A141S, G399S and R404W) as well as deactivation of the E3 ubiquitin-ligase parkin encoding gene. Furthermore, human cerebrospinal fluid or skin fibroblasts, monocytes, T-lymphocytes were analysed right up to nasal fluid samples in order to identify disease-related changes that may later on serve as diagnostic markers.
For the implementation of the above mentioned projects we, as the platform proteomics, collaborated with the various institutions involved in the project to conduct successfully comprehensive differential proteome analysis. The results of these studies were published in several scientific articles and further publications are in preparation. In some cases, the collaboration was even extended to additional studies. In addition, new partnerships with national and international partners were established resulting in different grant applications for further funding (DFG, DPG, EU and FoRUM).
The core facility proteomics was involved in the identification of potential protein biomarkers as well as the elucidation of pathomechanisms underlying Parkinson’s disease. We provided extensive knowledge in proteome analysis and analysed a variety of different samples types in tight collaboration with the different sub projects in the network.
Additional relevant Internet link: Medizinisches Proteom Center
Further Coordinators:
In total more than 400 differential proteins were identified in various MP-related projects. Hereto, model systems were used to examine mutational influences or to simulate the early phase of neurodegeneration. Besides various cell culture models also mouse models were investigated in which e.g. the influence of Parkinson's disease-related gene mutations were examined encoding for the protein alpha-synuclein (A30P and A53T) or the serine protease Omi/HtrA2 (A141S, G399S and R404W) as well as deactivation of the E3 ubiquitin-ligase parkin encoding gene. Furthermore, human cerebrospinal fluid or skin fibroblasts, monocytes, T-lymphocytes were analysed right up to nasal fluid samples in order to identify disease-related changes that may later on serve as diagnostic markers.
For the implementation of the above mentioned projects we, as the platform proteomics, collaborated with the various institutions involved in the project to conduct successfully comprehensive differential proteome analysis. The results of these studies were published in several scientific articles and further publications are in preparation. In some cases, the collaboration was even extended to additional studies. In addition, new partnerships with national and international partners were established resulting in different grant applications for further funding (DFG, DPG, EU and FoRUM).
The core facility proteomics was involved in the identification of potential protein biomarkers as well as the elucidation of pathomechanisms underlying Parkinson’s disease. We provided extensive knowledge in proteome analysis and analysed a variety of different samples types in tight collaboration with the different sub projects in the network.
Additional relevant Internet link: Medizinisches Proteom Center
KTT
MEDIA
CURRENT
NGFN-MEETING-2012
NGFN- MEETING
NGFN1&2
LINKS